Serotonin augmentation therapy by escitalopram has minimal effects on amyloid-β levels in early-stage Alzheimer’s-like disease in mice

BACKGROUND: Dysfunction of the serotonergic (5-HTergic) system has been implicated in the cognitive and behavioural symptoms of Alzheimer’s disease (AD). Accumulation of toxic amyloid-β (Aβ) species is a hallmark of AD and an instigator of pathology. Serotonin (5-HT) augmentation therapy by treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: von Linstow, Christian Ulrich, Waider, Jonas, Grebing, Manuela, Metaxas, Athanasios, Lesch, Klaus Peter, Finsen, Bente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596844/
https://www.ncbi.nlm.nih.gov/pubmed/28899417
http://dx.doi.org/10.1186/s13195-017-0298-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596844/
https://www.ncbi.nlm.nih.gov/pubmed/28899417
http://dx.doi.org/10.1186/s13195-017-0298-y

Ejemplares similares